表皮生长因子受体第20外显子插入突变：我们是否正在更接近解开谜团？ - Suppr

Suppr

超能文献

Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?

作者信息

Stinchcombe Thomas E

机构信息

Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA.

出版信息

Transl Lung Cancer Res. 2024 Nov 30;13(11):2864-2867. doi: 10.21037/tlcr-24-786. Epub 2024 Nov 12.

DOI:10.21037/tlcr-24-786

PMID:39670018

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11632422/

Abstract

摘要

相似文献

Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?表皮生长因子受体第20外显子插入突变：我们是否正在更接近解开谜团？

Transl Lung Cancer Res. 2024 Nov 30;13(11):2864-2867. doi: 10.21037/tlcr-24-786. Epub 2024 Nov 12.

Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.表皮生长因子受体外显子 20 插入突变的非小细胞肺癌的积极进展：一种新的靶向治疗选择。

J Oncol Pharm Pract. 2021 Dec;27(8):2007-2009. doi: 10.1177/10781552211044980. Epub 2021 Sep 27.

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展

J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].[携带表皮生长因子受体第20外显子插入突变的非小细胞肺癌的治疗进展]

Zhongguo Fei Ai Za Zhi. 2022 May 20;25(5):337-350. doi: 10.3779/j.issn.1009-3419.2022.103.01.

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.韩国晚期非小细胞肺癌中 EGFR 外显子 20 插入突变的临床结局。

Cancer Res Treat. 2019 Apr;51(2):623-631. doi: 10.4143/crt.2018.151. Epub 2018 Jul 23.

[Precise therapy for lung cancer patients with rare sensitive mutations of epidermal growth factor receptor].[针对具有罕见表皮生长因子受体敏感突变的肺癌患者的精准治疗]

Zhonghua Zhong Liu Za Zhi. 2017 Dec 23;39(12):881-884. doi: 10.3760/cma.j.issn.0253-3766.2017.12.001.

REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with exon 20 insertion-mutated NSCLC.REZILIENT3：一线使用齐帕替尼联合化疗治疗20号外显子插入突变非小细胞肺癌患者的随机III期研究

Future Oncol. 2025 Feb;21(5):549-556. doi: 10.1080/14796694.2025.2457294. Epub 2025 Feb 16.

Advances in the management of non-small-cell lung cancer harbouring exon 20 insertion mutations.携带20号外显子插入突变的非小细胞肺癌的治疗进展

Ther Adv Med Oncol. 2023 Jan 27;15:17588359221146131. doi: 10.1177/17588359221146131. eCollection 2023.

A novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib.表皮生长因子受体第20外显子上的一种新型插入突变，赋予对厄洛替尼的耐药性。

Case Rep Oncol. 2014 Jul 16;7(2):491-6. doi: 10.1159/000365325. eCollection 2014 May.

[The research status and development trend of EGFR gene exon 20 insertion mutant non-small cell lung cancer].表皮生长因子受体（EGFR）基因第20外显子插入突变型非小细胞肺癌的研究现状与发展趋势

Zhonghua Zhong Liu Za Zhi. 2020 Jan 23;42(1):22-29. doi: 10.3760/cma.j.issn.0253-3766.2020.01.003.

本文引用的文献

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.皮下注射与静脉注射 Amivantamab，均联合 Lazertinib，治疗难治性表皮生长因子受体突变型非小细胞肺癌：III 期 PALOMA-3 研究的主要结果。

J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.舒沃替尼用于中国铂类经治的局部晚期或转移性非小细胞肺癌及表皮生长因子受体第20外显子插入突变患者（WU-KONG6）：单臂、开放标签、多中心、2期试验

Lancet Respir Med. 2024 Mar;12(3):217-224. doi: 10.1016/S2213-2600(23)00379-X. Epub 2023 Dec 12.

Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。

N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.表皮生长因子受体 20 号外显子插入的非小细胞肺癌患者中 Zipalertinib 的安全性、耐受性和抗肿瘤活性。

J Clin Oncol. 2023 Sep 10;41(26):4218-4225. doi: 10.1200/JCO.23.00152. Epub 2023 Jun 29.

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.非小细胞肺癌中不常见的 EGFR 突变：患病率和临床结局的系统文献回顾。

Cancer Epidemiol. 2022 Feb;76:102080. doi: 10.1016/j.canep.2021.102080. Epub 2021 Dec 15.

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.比较伴有 EGFR 外显子 20 插入突变和常见 EGFR 突变的晚期 NSCLC 患者的临床结局。

Lung Cancer. 2021 Dec;162:154-161. doi: 10.1016/j.lungcan.2021.10.020. Epub 2021 Nov 6.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.在铂类预处理的 EGFR 外显子 20 插入阳性转移性非小细胞肺癌患者中莫博赛替尼的治疗结果和安全性：一项 1/2 期开放标签非随机临床试验。

JAMA Oncol. 2021 Dec 1;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761. Epub 2021 Dec 16.

Structure-based classification predicts drug response in EGFR-mutant NSCLC.基于结构的分类预测 EGFR 突变型 NSCLC 的药物反应。

Nature. 2021 Sep;597(7878):732-737. doi: 10.1038/s41586-021-03898-1. Epub 2021 Sep 15.

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.阿美替尼治疗 EGFR 外显子 20 插入突变型非小细胞肺癌：CHRYSALIS Ⅰ期研究的初步结果。

J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2.

Targeting exon 20 insertion mutations in non-small cell lung cancer.针对非小细胞肺癌中的外显子 20 插入突变。

Signal Transduct Target Ther. 2019 Mar 8;4:5. doi: 10.1038/s41392-019-0038-9. eCollection 2019.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验